Watch this video to learn how INOmax Total Care can support your NICU

INOmax Total Care can help you stay prepared for critical moments.

Trouble viewing this email?
View it online.

Please see Indication and Important Safety Information

INOmax Total Care^® helps support NICUs 24/7/365

Indication

INOMAX^® (nitric oxide) gas, for inhalation is indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents.

Select Important Safety Information

INOMAX is contraindicated in the treatment of neonates dependent on right-to-left shunting of blood.
Abrupt discontinuation of INOMAX may lead to increasing pulmonary artery pressure and worsening oxygenation.

See continued Important Safety Information below.

Did you know that INOmax Total Care helps ensure uninterrupted delivery to help mitigate the risk of device-related rebound pulmonary hypertension?^1,2 Contracted INOmax Total Care customers receive the drug, delivery systems, and 24/7/365 service and support to help support NICUs when it’s needed most.

Watch a brand-new video available on inomax.com/inomax-total-care to learn how INOmax Total Care supports customers nationwide, from emergency deliveries to in-person device training to round-the-clock customer care and technical support provided by experienced personnel.

Visit inomax.com/inomax-total-care for more information and to view additional videos on the INOmax Total Care experience.

Stay prepared for when critical moments arise.

Important Safety Information, continued

Methemoglobinemia and NO₂ levels are dose dependent. Nitric oxide donor compounds may have an additive effect with INOMAX on the risk of developing methemoglobinemia. Nitrogen dioxide may cause airway inflammation and damage to lung tissues.
In patients with pre-existing left ventricular dysfunction, INOMAX may increase pulmonary capillary wedge pressure leading to pulmonary edema.
Monitor for PaO₂, inspired NO₂, and methemoglobin during INOMAX administration.
INOMAX must be administered using a calibrated FDA-cleared Nitric Oxide Delivery System.

Applications

The INOmax DS_IR^® Plus Delivery Systems deliver INOMAX^® (nitric oxide) gas, for inhalation. The INOmax DS_IR Plus Delivery Systems must only be used in accordance with the indications, usage, contraindications, and warnings and precautions described in the INOMAX package inserts and labeling. The approved patient population is limited to neonates. Refer to the INOMAX Full Prescribing Information prior to use.

Device Warnings

Abrupt discontinuation of INOMAX can lead to worsening oxygenation and increasing pulmonary artery pressure (rebound pulmonary hypertension syndrome). To avoid abrupt discontinuation, use the INOblender^® or backup mode immediately to reinstate INOMAX therapy and refer to the INOMAX package insert.
If the high NO₂ alarm activates, the delivery system should be assessed for proper setup while maintaining INOMAX delivery.
Do not connect items that are not specified as part of the system.
If an alarm occurs, safeguard the patient first before troubleshooting or repair procedures.
Use only INOMAX, pharmaceutical grade NO/N₂.

Rx Only

Consult the Operation and Maintenance Manual, which may be found at www.inomax.com/training-and-education/device-support-resources, for complete information. For technical assistance, call (877) 566-9466.

References: 1. INOmax DS_IR^® Plus: Operation Manual. Mallinckrodt Pharmaceuticals Manufacturing, LLC; 2017:1-206. 2. INOmax DS_IR^® Plus MRI: Operation Manual. (Software V.3). Mallinckrodt Pharmaceuticals Manufacturing, LLC; 2015:1-154.

To ensure you receive emails from INOMAX, add TotalCare-INFO@MNK.com to your address book.

Please note that you have received this email as part of a marketing distribution.

If you no longer wish to receive such marketing emails regarding INOMAX, please click here to unsubscribe.

If you no longer wish to receive such marketing emails from Mallinckrodt Pharmaceuticals, please click here to unsubscribe.

Mallinckrodt, the “M” brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company. Other brands are trademarks of a Mallinckrodt company or their respective owners.